Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) - 1 Mar 2012

Přikrylová Vranová Hana, Mareš Jan, Hluštík Petr, Nevrlý Martin, Stejskal David, Zapletalová Jana, Obereigneru Radko, Kaňovský Petr

Abstract excerpt

Parkinson's disease (PD) is a neurodegenerative disorder with highly heterogeneous clinical manifestations. This fact has prompted many attempts to divide PD patients into clinical subgroups. This could lead to a better recognition of pathogenesis, improving targeted treatment and the prognosis of PD patients. The aim of the present study was to obtain cerebrospinal fluid (CSF) samples in PD patients and to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Amyloid beta-Peptides

Share to Neuropsychological Tests

Share to Parkinson Disease

Share to Peptide Fragments

Share to Phenotype

Share to tau Proteins

Source

Identifiers

PMID: 21892760
DOI: 10.1007/s00702-011-0708-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.PMID 21892760Read ↗

CSF biomarkers in different phenotypes of Parkinson disease.Semantic proximity Read ↗

Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.Semantic proximity Read ↗

Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.Semantic proximity Read ↗

Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s diseaseSemantic proximity Read ↗

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.Semantic proximity Read ↗

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Semantic proximity Read ↗

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism SyndromesSemantic proximity Read ↗

The Use of Proteomics in Biomarker Discovery in Neurodegenerative DiseasesSemantic proximity Read ↗

Phenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters.Semantic proximity Read ↗

CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity.Semantic proximity Read ↗

Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases.Semantic proximity Read ↗

Cerebrospinal Fluid Biomarker Profile in TDP-43-Related Genetic Frontotemporal DementiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.